Geneyx
Geneyx is an Israeli healthtech company that provides an AI-powered tertiary analysis platform for interpreting next-generation sequencing data, serving hospitals, clinical diagnostic labs, and academic medical centers across 36+ countries.
- Company typePrivate
- Founded2018
- HeadquartersHerzliya, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Geneyx does
Geneyx Genomex Ltd. is a privately-held Israeli health technology company that develops Geneyx Analysis, an AI-powered tertiary analysis platform for interpreting next-generation sequencing (NGS) data including whole genome sequencing, whole exome sequencing, gene panels, and microarrays. The platform combines automated bioinformatics pipelines with machine learning-based variant prioritization that integrates phenotypic data (HPO terms) and curated literature, alongside ACMG-compliant classification. It supports both short-read sequencing via the embedded Illumina DRAGEN secondary pipeline and long-read sequencing from PacBio HiFi and Oxford Nanopore, with extensions into multi-omics DNA+RNA analysis (via the SVDuo/Ocean Genomics/Omics Discoveries collaboration), methylation analysis, phasing, and a pharmacogenomics module covering 87 genes and 321+ drugs.
The company operates a subscription-based enterprise SaaS model with both cloud and on-premise deployment, sold primarily through direct field sales to hospitals, clinical diagnostic laboratories, and academic medical centers, supplemented by regional distributors covering EMEA, APAC, LATAM, the Middle East (via Digi7), and Africa (via Inqaba Biotec). Customers enter Master Software Subscription and Services Agreements with annual billing, and multiple relationships are documented at 4-6 year tenure, including IRCCS Bambino Gesù (Italy, extended 6 years), University of Hong Kong, and Hospital Universitari Son Espases. The platform holds ISO 13485:2016, ISO/IEC 27001:2022, ISO 27799:2016, HIPAA, GDPR, UK NHS Data Security and Protection Toolkit, and Cyber Essentials certifications — a regulatory stack required for clinical procurement.
Geneyx is integrated as the official tertiary analysis partner for Oxford Nanopore (EPI2ME), PacBio (Sequel II/IIe/Revio Compatible program), and Illumina (DRAGEN), and was selected into the Google AI First Accelerator in 2024. The company has raised $6.5 million in seed funding (November 2021, Capri + Accenture Ventures), maintains offices in Herzliya (HQ), Wilmington DE, and Heerlen (Netherlands), and serves approximately 2,000 active users analyzing 500,000+ clinical cases across 36 countries. It operates with a lean headcount of 11-50 employees.
Geneyx firmographics
Firmographics- Name
- Geneyx
- Legal name
- Geneyx Genomex Ltd.
- Website
- https://geneyx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Geneyx is an Israeli healthtech company that provides an AI-powered tertiary analysis platform for interpreting next-generation sequencing data, serving hospitals, clinical diagnostic labs, and academic medical centers across 36+ countries.
- Ownership category
- akta.pro rank
Geneyx industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
- akta.pro secondary industries
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Geneyx is headquartered
LocationHeadquarters
- HQ city
- Herzliya
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Geneyx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Geneyx Analysis Software Subscriptions: Geneyx generates revenue through software subscription agreements (Master Software Subscription and Services Agreement) for access to the Geneyx Analysis platform. Customers include hospitals, clinical diagnostic companies, and academic institutions. The platform is offered as a cloud-based SaaS solution with on-premise capability.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Platform access with subscription-based pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Geneyx product offering
Product offeringCore offering
Geneyx develops and sells Geneyx Analysis, an AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of next-generation sequencing (NGS) data — including whole-genome sequencing (WGS), whole-exome sequencing (WES), gene panels, microarrays, and long-read (PacBio HiFi, Oxford Nanopore) data. The platform automates variant annotation, ACMG-based classification, phenotypic prioritization, multi-omics (DNA + RNA + methylation) interpretation, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.
Product overview
Geneyx offers a unified platform architecture centered on Geneyx Analysis as the core product, complemented by specialized modules including Geneyx MultiOmics for integrated DNA/RNA/epigenetics analysis, Long-Read Analysis for PacBio and Oxford Nanopore sequencing data, and Geneyx Pharmacogenomics covering 87 genes and 321+ drugs. The SVDuo module (co-developed with Ocean/Omics Discoveries) enables combined DNA and RNA analysis for enhanced structural variant detection. Geneyx Clinical Apps provides clinical interpretation services. All products share a common AI-powered annotation and visualization engine within Geneyx Analysis, which serves as the central platform for variant prioritization, filtering, interpretation, and clinical reporting across all sequencing modalities.
Differentiator
Problem solved
Functional benefit
Brands
- Geneyx Analysis: AI-Based Genetic Data Analysis and Interpretation Solution for WGS, WES, Gene Panels, and Microarrays.
- Geneyx Clinical Apps
- Geneyx MultiOmics
- SVDuo
Products and services
- Geneyx Analysis AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of NGS data (WGS, WES, gene panels, microarrays, and long-read). Automates variant annotation, ACMG classification, phenotypic prioritization, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.
- Geneyx MultiOmics Multi-omics analysis product that combines DNA, RNA, and epigenetics (methylation) data for enhanced variant detection and functional genomics interpretation, built jointly with Omics Discoveries.
- Long-Read Analysis Long-read sequencing analysis product compatible with PacBio HiFi (Sequel II, IIe, Revio) and Oxford Nanopore data, supporting phasing, methylation analysis, and structural variant detection.
- Geneyx Pharmacogenomics Comprehensive pharmacogenomics workflow covering 87 genes and 321+ drugs, aligned with CPIC and PharmGKB levels; provides drug metabolism interpretations and clinical recommendations for 13 CPIC Level A/B genes affecting 68+ commonly prescribed drugs.
- Geneyx Clinical Apps Clinical interpretation services that deliver accurate, compliant, and signed clinical reports for healthcare providers, including pharmacogenomics reporting.
- SVDuo Integrated DNA and RNA analysis software co-developed with Ocean Genomics/Omics Discoveries, designed to enhance genomic variant detection by revealing previously undetectable structural variants through combined DNA and RNA analysis.
Quantifiable outcome
- Hospitals report analyzing up to 15,000 samples/year with Geneyx Analysis, up from 400 samples/year before adoption
- +2 more outcomes
Companies that use Geneyx
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Geneyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability6 records
Feature12 records
Geneyx partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, strategic and minor.
- Omics DiscoveriescorePartnership between Geneyx and Omics Discoveries (Munich, Germany) to advance functional genomics through integrated DNA-RNA analysis. Geneyx Analysis AI-based genomic interpretation engine is combined with Omics Discoveries' RNA-seq technology to offer clinical geneticists an integrated view of DNA, RNA, and phenotype data. Expected commercial availability within six months of announcement.
- Google (AI First Accelerator)strategicGeneyx was selected into Google's AI First Accelerator program - a 10-week program for AI-first startups in Europe and Israel. Benefits include Google Cloud credits, mentorship from Google Cloud and Google DeepMind, workshops on product design and business growth, and connections to venture capitalists and investors.
- Children's Mercy Kansas CitycoreResearch collaboration through a Master Software Subscription and Services Agreement enabling Children's Mercy to use Geneyx Analysis for analyzing PacBio HiFi long-read sequencing data. Children's Mercy is the first healthcare system to use advanced genomic sequencing technology as first-line assessment for critically ill pediatric patients with suspected genetic disease. Geneyx provides genomic training, research, and analysis support.
- PacBiocoreGeneyx is listed as a PacBio Compatible tertiary analysis partner for HiFi long-read sequencing data on PacBio's Sequel II, Sequel IIe, and Revio systems. Geneyx enables PacBio customers to leverage HiFi data for rare and inherited disease research with features including phasing and methylation analysis. Partnership maximizes value of HiFi data and completes the end-to-end workflow for PacBio customers.
- Ocean GenomicscoreJoint development partnership with Ocean Genomics (later renamed/partnership continued as Omics Discoveries) to develop multi-omic software combining DNA and RNA analysis for improved detection of genomic variants. Funded by the BIRD Foundation. The collaboration aims to enhance disease diagnosis and drug target identification through integrated DNA-RNA analysis. SVDuo product released as a result.
- Oxford Nanopore TechnologiescoreStrategic technology partnership to develop the first scalable end-to-end software solution for clinical reporting of nanopore sequencing data. Geneyx Analysis integrates with Oxford Nanopore's EPI2ME cloud platform for secondary-to-tertiary analysis workflow. The partnership includes pilot projects with Digi7 and Mediclinic Middle East. Target applications include newborn screening and rare/undiagnosed disease research.
- Mediclinic Middle EastminorMediclinic Middle East partnered with Geneyx through Digi7 to implement AI-based genomic analysis at Mediclinic hospitals in Abu Dhabi and Dubai, UAE. Geneyx showcases its capabilities with a highly respected healthcare provider to gain feedback and establish market presence in the Middle East region.
- Inqaba BiotecminorRegional distributor for Geneyx Analysis in Africa. Inqaba Biotec, based in South Africa, distributes and supports Geneyx Analysis across African markets, providing local sales, implementation, and customer support.
- Digi7minorRegional distribution partner in the Middle East. Digi7 launched Geneyx AI-based solution at Mediclinic hospitals in Abu Dhabi and Dubai, UAE, serving as a local implementation and support partner.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Geneyx competitors and assessment
Company assessmentDirect peers
- SOPHiA GENETICS: Public clinical genomics interpretation platform offering SOPHiA DDM for hereditary disease, oncology, and pharmacogenomics. Directly comparable to Geneyx Analysis as a tertiary interpretation SaaS sold to hospitals and clinical labs, with overlapping modules (CNV/SV, ACMG classification, RNA analysis) and similar buyer personas.
- Fabric Genomics: Clinical AI genomics interpretation platform focused on rare disease diagnosis and hereditary cancer, with Fabric Enterprise and Fabric Clinical products. Directly comparable in use case (rare disease tertiary interpretation), AI-driven variant prioritization, and clinical reporting.
- Congenica: UK-based clinical genomic interpretation platform for rare disease and somatic cancer, sold into hospitals and national genomics programs. Directly comparable in ACMG-aligned variant classification, clinical reporting, and rare disease workflows, and a competing choice in NHS/UK procurements.
Broad incumbents
- QIAGEN Digital Insights (Ingenuity, QCI): QIAGEN's clinical genomics software business offering Ingenuity Variant Analysis, QCI Interpret, and QCI Precision Insights. A broad incumbent in tertiary analysis serving pharma, clinical labs, and academic customers with overlapping variant interpretation and clinical reporting capabilities.
- DNAnexus: Enterprise genomic and biomedical data analysis platform used by pharma, clinical labs, and consortia for NGS processing at scale. Overlaps with Geneyx in clinical and research genomics workflows, with broader scope across pharma R&D and a more infrastructure/data-platform positioning.
Emerging players
- Molecular Health: Heidelberg-based clinical genomics decision support for rare disease and oncology, including MH Guide and Dataome. Comparable as a clinical interpretation platform targeting hospitals and rare disease programs, with overlapping pharmacogenomics and somatic interpretation use cases.
- Lifebit: Cloud genomics and biomedical data platform serving pharma, consortia, and public health genomics with federated analysis capabilities. Comparable as a software platform for genomic data analysis and interpretation, with overlapping enterprise and academic buyer personas.
Regional players
- BC Platforms: European genomics and real-world data platform providing clinical interpretation, biobank analytics, and genomic data management. Comparable as a clinical genomics software vendor in Europe with overlapping rare disease and pharmacogenomics interpretation capabilities.
Others
- BlueBee (acquired by Illumina): Genomic data management and analysis platform originally independent, now part of Illumina's bioinformatics portfolio (including DRAGEN-related cloud offerings). Adjacent/complementary to Geneyx through the DRAGEN integration ecosystem, with comparable cloud NGS analysis use cases.
- BioMarin (genomic analytics adjacent): Not a direct software peer, but referenced here as a representative pharma/rare disease buyer ecosystem for clinical genomic interpretation tools. Listed for ecosystem context given Geneyx's stated focus on rare disease customers and pharma-adjacent translational research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Geneyx social profiles
Digital presenceGeneyx compliance and trust
Trust signalCompliance7 records
Geneyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Geneyx leadership team
Management profileNumber of profiles
Profiles6 records
Geneyx subsidiaries and ownership
Company hierarchySubsidiaries1 record
Geneyx funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Geneyx M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Geneyx
What does Geneyx do?
Geneyx develops and sells Geneyx Analysis, an AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of next-generation sequencing (NGS) data — including whole-genome sequencing (WGS), whole-exome sequencing (WES), gene panels, microarrays, and long-read (PacBio HiFi, Oxford Nanopore) data. The platform automates variant annotation, ACMG-based classification, phenotypic prioritization, multi-omics (DNA + RNA + methylation) interpretation, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.
Is Geneyx a public or private company?
Geneyx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Geneyx founded?
Geneyx was founded in 2018. It employs 11 to 50 people.
Where is Geneyx based?
Geneyx is headquartered in Herzliya, Israel, in the Middle East region.
How does Geneyx make money?
One revenue line is on record: geneyx Analysis Software Subscriptions.
Who are Geneyx's main competitors?
Direct peers on record are SOPHiA GENETICS, Fabric Genomics and Congenica. Broad incumbents are QIAGEN Digital Insights (Ingenuity, QCI) and DNAnexus. Emerging players are Molecular Health and Lifebit. BC Platforms is listed as a regional player. Others are BlueBee (acquired by Illumina) and BioMarin (genomic analytics adjacent).
Does Geneyx have an API?
Yes. Geneyx Analysis provides API capabilities including a new endpoint to programmatically retrieve TSV files, enhancing integration with downstream tools and pipelines. Version 6.2 introduced improved API capabilities. Version 5.9 mentions that new API scripts are available with updated details to improve usability. External JSON files from DRAGEN special callers can be uploaded via the API.
What industry is Geneyx in?
Geneyx's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 7370.